gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ASMBHealthcarePharmaceuticals

Assembly Biosciences, Inc (ASMB)

$19.87−0.25%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.97▼ 35.93% in range
Nov 3, 2025Low $19.51 · High $38.50Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Assembly Biosciences closed at $19.87 on Nov 4, down 0.25%, within 1.8% of its 52-week closing low. Volume of 269.2K shares was 1.34× its 20-day average (above normal).

Split-adjusted performance: -10.4% over one month, -36.6% over six months, -36.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $13.37M, up 38.9% from a year earlier, with a net margin of -28.8%.

Short interest was 2.9M shares at the Oct 15 settlement, up 3.2% from the prior report (28.0% of float, 11.1 days to cover).

Market cap$404.6M20.4M shares
Revenue · quarter$13.4M+38.9% YoY
Diluted EPS$-0.20—
P/E · TTM—P/S 5.4×
Net margin-28.8%Gross 100.0%
Dividend yieldNone
52-week range19.51 – 38.50−48.4% from high
Volume269.2K1.34× 20-day avg
Volatility · 60d63.6%Annualised
Short % of float28.0%11.1 days to cover
Net cash$320.4MCash $320.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.4%1M −10.4%3M −24.9%6M −36.6%YTD −41.6%1Y −36.3%3Y +90.3%5Y −46.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum36
Revenue growth76
Net margin52
Value (low P/E)—
Size58

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.9M+3.2% vs prior
Days to cover11.1Settled Oct 15
% of float28.0%
Short vol. 10d63.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ASMBAssembly Biosciences$19.87−0.25%−36.6%+38.9%−28.8%—$404.6M
ALTAltimmune$2.12+3.92%−35.0%−100.0%——$412.4MCompare
BLSMBlossomHill Therapeutics$12.38−0.24%————$393.5MCompare
RZLTRezolute, Inc. Common Stock (NV)$3.96−1.25%+26.1%———$383.0MCompare
PRTAProthena$8.39+2.19%−25.0%−77.1%−1839.9%—$430.7MCompare
AVTXAvalo Therapeutics$7.07−2.48%−67.6%———$379.2MCompare
LYELLyell Immunopharma$15.43+43.27%−26.0%−50.0%−1118875.0%—$378.1MCompare
TLRYTilray Brands$2.96+11.70%−48.6%+22.7%−16.8%—$437.5MCompare
MPLTMapLight Therapeutics$6.71−1.47%−76.9%———$372.9MCompare

News about Assembly Biosciences

All news →
Assembli to Produce Big Ten Conference Activation at Fanatics Fest in New YorkGlobeNewswire Inc. · Jul 16, 2026▲ PositiveAssembly Biosciences to Present at the BofA Securities 2026 Global Health Care ConferenceGlobeNewswire Inc. · May 11, 2026▲ PositiveAssembly Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsGlobeNewswire Inc. · May 7, 2026▲ Positive

Quick answers

What does Assembly Biosciences do?
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points.
What is ASMB's market cap?
$404.57M, based on the Nov 4 close of $19.87.
Does Assembly Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ASMB is sold short?
2.9M shares, 28.0% of float, as of Oct 15, 2026.
What sector is ASMB in?
Healthcare, in the Pharmaceuticals industry.

About Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

HQ: South San Francisco, CA73 employeesListed Dec 17, 2010assemblybio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology